Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 10,573 | 0.74 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8932
Sealed predictions
- NF1 in dopamine neurons, braak+0.47 (p 0.197) → +0.11 (p 0.780)receipt 8939
Swarm cases
receipt 8939: NF1 in dopamine neurons, braak
- power
- full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.997, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.627, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.10, sign flips 6; without severely affected donors +0.01 (p 0.962, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.69 (p 0.0015, n 18) vs +0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NF1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NF1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.60 p 0.033 (needs p < 2.4e-4)
Receipts
loading the receipts